{"nctId":"NCT03620981","briefTitle":"Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type","startDateStruct":{"date":"2018-08-20","type":"ACTUAL"},"conditions":["Agitation Associated With Dementia of the Alzheimer's Type"],"count":410,"armGroups":[{"label":"Brexpiprazole, 1mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Brexpiprazole"]},{"label":"Brexpiprazole, 2mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Brexpiprazole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Brexpiprazole","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who satisfy both of the following diagnostic criteria:\n\n  1. Diagnosis of \"Dementia due to Alzheimer's Disease\" according to DSM-5.\n  2. Diagnosis of \"Probable Alzheimer's Disease\" according to NINCDS-ADRDA.\n* Hospitalized patients or care facility patients or care at home patients\n* Patients with an MMSE score of 1 to 22\n* Patients who have the agitation defined according to the \"Consensus provisional definition of agitation in cognitive disorders\" from the International Psychogeriatric Association (IPA)\n\nExclusion Criteria:\n\n* Patients who have dementia other than dementia of the Alzheimer's type\n* Patients diagnosed with delirium between 30 days before the screening examination and baseline evaluation according to DSM-5.\n* Patients diagnosed with any of the following disorders according to DSM-5:\n\n  * Schizophrenia spectrum and other psychotic disorders\n  * Bipolar and related disorders\n  * Major depressive disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing.","description":"The CMAI assessed the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consisted of 29 items all rated on a 1 to 7 scale with 1 being the \"best\" rating and 7 being the \"worst\" rating. The minimum possible CMAI total score was 29, and the maximum possible CMAI total score was 203. A decrease in score indicated improvement in symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"1.20"},{"groupId":"OG001","value":"-15.2","spread":"1.05"},{"groupId":"OG002","value":"-8.0","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at 10 Weeks After Dosing.","description":"The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicated improvement in symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.1"},{"groupId":"OG001","value":"-1.4","spread":"0.09"},{"groupId":"OG002","value":"-0.6","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Improvement (CGI-I) Score at 10 Weeks After Dosing.","description":"The CGI-I Scale was clinician-rated scale which assessed the total improvement of the patient's condition compared to that at baseline. Scores range from 0 to 7: 0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.3"},{"groupId":"OG001","value":"2.6","spread":"1.2"},{"groupId":"OG002","value":"3.5","spread":"1.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":112},"commonTop":["Insomnia","Contusion","Somnolence","Fall","Pyrexia"]}}}